Tumor suppressor gene promoter region methylation

**Tumor suppressor gene promoter region methylation** refers to the addition of methyl groups to CpG islands in the promoter regions of tumor suppressor genes. This epigenetic modification leads to chromatin condensation, transcriptional repression, and functional silencing of these genes without altering their DNA sequence[1][2][3][4][6]. Loss of tumor suppressor gene function contributes to oncogenesis by allowing uncontrolled cell proliferation, failure of DNA repair, and evasion of apoptosis. Promoter hypermethylation of genes like CDKN2A (p16), CDKN2B (p15), RB1, BRCA1, DAPK1, and MGMT is observed in multiple cancers and may be a poor prognostic indicator[1][4][5][6][7]. Hypermethylation is reversible, and demethylating agents can restore gene expression, making methylation patterns both potential therapeutic targets and important biomarkers in clinical oncology[4][7]. However, as an epigenetic change rather than a discrete molecular entity (like a receptor or enzyme), "tumor suppressor gene promoter region methylation" describes a molecular process, not a single drug target, and should be considered a biomarker or therapeutic mechanism, not a canonical target itself. Caveat: The queried target is not a single gene or protein but a class of molecular epigenetic events affecting many tumor suppressor genes – it is not accurate to treat this as a canonical drug target/receptor. It is more appropriately referenced as a *modification type* or *mechanistic process* in cancer biology and therapy.

Other names

Promoter methylation of tumor suppressor geneTumor suppressor gene hypermethylationTumor suppressor gene epimutationTumor suppressor gene silencing (via methylation)

Reactivation of silenced tumor suppressor genes by inhibiting DNA methyltransferases[4]; Demethylation of CpG islands in promoter regions[4]